Table 2

Response and drug survival rate in AS patients treated with TNF-α blocking therapy

Total

IFX

ETA

ADA

Number of patients

220

32

137

51

ASAS20 responders at three months

68%

80%

66%

65%

(number of patients)

(145 of 214)

(24 of 30)

(88 of 133)

(33 of 51)

ASAS20 responders at six months

63%

71%

66%

51%

(number of patients)

(132 of 209)

(22 of 31)

(86 of 131)

(24 of 47)

ASAS40 responders at three months

49%

63%

47%

45%

(number of patients)

(104 of 214)

(19 of 30)

(62 of 133)

(23 of 51)

ASAS40 responders at six months

46%

52%

48%

38%

(number of patients)

(97 of 209)

(16 of 31)

(63 of 131)

(18 of 47)

BASDAI50 responders at three months

49%

60%

46%

51%

(number of patients)

(105 of 214)

(18 of 30)

(61 of 133)

(26 of 51)

BASDAI50 responders at six months

50%

48%

51%

47%

(number of patients)

(104 of 209)

(15 of 31)

(67 of 131)

(22 of 47)

One-year drug survival

71%

76%

72%

65%

(number of patients)

(136 of 192)

(22 of 29)

(88 of 123)

(26 of 40)

Two-year drug survival

66%

70%

69%

48%

(number of patients)

(97 of 148)

(19 of 27)

(66 of 96)

(12 of 25)

See Table 1 for definitions.

No statistical differences were found between treatment groups (P ≥0.05).

Arends et al. Arthritis Research & Therapy 2011 13:R94   doi:10.1186/ar3369